[{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for MolPort-001-738-424
USFDA has granted orphan drug designation for the combination of ocaliva (obeticholic acid), a farnesoid X receptor agonist and bezafibrate, a PPAR agonist, for the treatment of individuals with primary biliary cholangitis.
Bezafibrate, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, has been studied for the treatment of PBC, carries the potential to help patients achieve reductions in ALP and bilirubin while improving pruritus.